Strain Name:

C.129S4(B6)-Miftm1Dvd/J

Stock Number:

003830

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Specieslaboratory mouse
 
Donating Investigator John R. David,   Harvard School of Public Health

Description
Mice that are homozygous null for the Mif gene are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. No Mif gene product (mRNA or protein) is detected. While null mice exhibit signs of endotoxemia in response to intraperitoneally injected LPS (25 mg/kg), they are resistant to its lethal effects. Plasma levels of tumor necrosis factor alpha assayed after LPS administration is half that observed in wildtype mice.

Development
A targeting vector containing a neomycin resistance gene and a herpes simplex virus thymidine kinase gene was used to disrupt exons 2 and 3. The construct was electroporated into 129S4/SvJae-derived J1 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6 blastocysts. The resulting chimeric animals were backcrossed to BALB/cAnNTac mice.

Related Strains

Strains carrying other alleles of Mif
020652   B6.Cg-Tg(tetO-Mif)279Aren/J
012304   C57BL/6-Miftm2Gfr/Mmjax
View Strains carrying other alleles of Mif     (2 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Rheumatoid Arthritis, Systemic Juvenile   (MIF)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Miftm1Dvd/Miftm1Dvd

        involves: 129S4/SvJae * C57BL/6
  • immune system phenotype
  • decreased circulating tumor necrosis factor level
    • mutants stimulated with LPS or SEB show a 50% and 65%, respectively, reduction in the plasma levels of TNF-alpha compared to wild-type   (MGI Ref ID J:52300)
    • macrophages stimulated with LPS and interferon gamma show diminished production of TNF-alpha   (MGI Ref ID J:52300)
  • decreased susceptibility to bacterial infection
    • mutants clear gram-negative bacteria Pseudomonas aeruginosa instilled into the trachea better than wild-type and have diminished neutrophil accumulation in their bronchoalveolar fluid compared to wild-type   (MGI Ref ID J:52300)
  • decreased susceptibility to endotoxin shock
    • mutants are resistant to the lethal effects of high dose bacterial lipopolysaccharide (LPS) and Staphylococcus aureus enterotoxin B (SEB) with D-galactosamine   (MGI Ref ID J:52300)
    • however, mutants are susceptible to a combination of low-dose LPS and D-galactosamine   (MGI Ref ID J:52300)
  • increased interleukin-4 secretion
    • lymph node cells from L. major infected mice show higher IL-4 production after antigen stimulation than cells from wild-type   (MGI Ref ID J:52300)
  • increased susceptibility to parasitic infection
    • mice are more susceptible to the intracellular parasite L. major than wild-type   (MGI Ref ID J:52300)
  • homeostasis/metabolism phenotype
  • decreased circulating tumor necrosis factor level
    • mutants stimulated with LPS or SEB show a 50% and 65%, respectively, reduction in the plasma levels of TNF-alpha compared to wild-type   (MGI Ref ID J:52300)
    • macrophages stimulated with LPS and interferon gamma show diminished production of TNF-alpha   (MGI Ref ID J:52300)

Miftm1Dvd/Miftm1Dvd

        B6.129S4-Miftm1Dvd
  • tumorigenesis
  • decreased incidence of tumors by chemical induction
    • mice treated with N-butyl-N-(-4-hydroxybutyl)-nitrosamine (BBN) develop less aggressive bladder cancer than wild-type mice, with no invasion into muscle layers as seen in wild-type   (MGI Ref ID J:126543)
  • homeostasis/metabolism phenotype
  • decreased incidence of tumors by chemical induction
    • mice treated with N-butyl-N-(-4-hydroxybutyl)-nitrosamine (BBN) develop less aggressive bladder cancer than wild-type mice, with no invasion into muscle layers as seen in wild-type   (MGI Ref ID J:126543)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Miftm1Dvd related

Immunology, Inflammation and Autoimmunity Research
Growth Factors/Receptors/Cytokines

Research Tools
Immunology, Inflammation and Autoimmunity Research
      lipopolysaccharide resistant congenic

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Miftm1Dvd
Allele Name targeted mutation 1, John R David
Allele Type Targeted (Null/Knockout)
Common Name(s) MIF-; MIF-KO;
Mutation Made By John David,   Harvard School of Public Health
Strain of Origin129S4/SvJae
ES Cell Line NameJ1
ES Cell Line Strain129S4/SvJae
Gene Symbol and Name Mif, macrophage migration inhibitory factor
Chromosome 10
Gene Common Name(s) GIF; GLIF; Glif; MMIF; glycosylation inhibiting factor;
Molecular Note A neomycin resistance cassette replaced a genomic fragment containing part of exon 2 and exon 3. Northern blot analysis on RNA derived from liver of LPS-treated homozygous mice demonstrated that no detectable transcript was produced form this allele. ELISA assays on serum of LPS-treated animals confirmed that no functional protein was expressed from this allele. [MGI Ref ID J:52300]

Genotyping

Genotyping Information

Genotyping Protocols

Miftm1DvdAlternative2, Separated PCR
Miftm1Dav, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Bozza M; Satoskar AR; Lin G; Lu B; Humbles AA; Gerard C; David JR. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189(2):341-6. [PubMed: 9892616]  [MGI Ref ID J:52300]

Additional References

Miftm1Dvd related

Aeberli D; Yang Y; Mansell A; Santos L; Leech M; Morand EF. 2006. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett 580(3):974-81. [PubMed: 16442105]  [MGI Ref ID J:105577]

Alexander JK; Cox GM; Tian JB; Zha AM; Wei P; Kigerl KA; Reddy MK; Dagia NM; Sielecki T; Zhu MX; Satoskar AR; McTigue DM; Whitacre CC; Popovich PG. 2012. Macrophage migration inhibitory factor (MIF) is essential for inflammatory and neuropathic pain and enhances pain in response to stress. Exp Neurol 236(2):351-62. [PubMed: 22575600]  [MGI Ref ID J:187074]

Amaral FA; Fagundes CT; Guabiraba R; Vieira AT; Souza AL; Russo RC; Soares MP; Teixeira MM; Souza DG. 2007. The role of macrophage migration inhibitory factor in the cascade of events leading to reperfusion-induced inflammatory injury and lethality. Am J Pathol 171(6):1887-93. [PubMed: 18055556]  [MGI Ref ID J:128947]

Arenberg D; Luckhardt TR; Carskadon S; Zhao L; Amin MA; Koch AE. 2010. Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair. Am J Respir Crit Care Med 182(8):1030-7. [PubMed: 20581170]  [MGI Ref ID J:191115]

Assuncao-Miranda I; Amaral FA; Bozza FA; Fagundes CT; Sousa LP; Souza DG; Pacheco P; Barbosa-Lima G; Gomes RN; Bozza PT; Da Poian AT; Teixeira MM; Bozza MT. 2010. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J 24(1):218-28. [PubMed: 19776337]  [MGI Ref ID J:156645]

Atsumi T; Cho YR; Leng L; McDonald C; Yu T; Danton C; Hong EG; Mitchell RA; Metz C; Niwa H; Takeuchi J; Onodera S; Umino T; Yoshioka N; Koike T; Kim JK; Bucala R. 2007. The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J Immunol 179(8):5399-406. [PubMed: 17911626]  [MGI Ref ID J:153024]

Bank LM; Bianchi LM; Ebisu F; Lerman-Sinkoff D; Smiley EC; Shen YC; Ramamurthy P; Thompson DL; Roth TM; Beck CR; Flynn M; Teller RS; Feng L; Llewellyn GN; Holmes B; Sharples C; Coutinho-Budd J; Linn SA; Chervenak AP; Dolan DF; Benson J; Kanicki A; MartinCA; Altschuler R; Koch AE; Jewett EM; Germiller JA; Barald KF. 2012. Macrophage migration inhibitory factor acts as a neurotrophin in the developing inner ear. Development 139(24):4666-74. [PubMed: 23172918]  [MGI Ref ID J:189954]

Cox GM; Kithcart AP; Pitt D; Guan Z; Alexander J; Williams JL; Shawler T; Dagia NM; Popovich PG; Satoskar AR; Whitacre CC. 2013. Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation. J Immunol 191(3):1043-54. [PubMed: 23797673]  [MGI Ref ID J:205729]

Flores M; Saavedra R; Bautista R; Viedma R; Tenorio EP; Leng L; Sanchez Y; Juarez I; Satoskar AA; Shenoy AS; Terrazas LI; Bucala R; Barbi J; Satoskar AR; Rodriguez-Sosa M. 2008. Macrophage migration inhibitory factor (MIF) is critical for the host resistance against Toxoplasma gondii. FASEB J 22(10):3661-71. [PubMed: 18606868]  [MGI Ref ID J:140243]

Gadjeva M; Nagashima J; Zaidi T; Mitchell RA; Pier GB. 2010. Inhibition of macrophage migration inhibitory factor ameliorates ocular Pseudomonas aeruginosa-induced keratitis. PLoS Pathog 6(3):e1000826. [PubMed: 20361053]  [MGI Ref ID J:162952]

Harper JM; Wilkinson JE; Miller RA. 2010. Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction. FASEB J 24(7):2436-42. [PubMed: 20219983]  [MGI Ref ID J:162354]

Hoi AY; Hickey MJ; Hall P; Yamana J; O'Sullivan KM; Santos LL; James WG; Kitching AR; Morand EF. 2006. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 177(8):5687-96. [PubMed: 17015758]  [MGI Ref ID J:139429]

Jacquin C; Koczon-Jaremko B; Aguila HL; Leng L; Bucala R; Kuchel GA; Lee SK. 2009. Macrophage migration inhibitory factor inhibits osteoclastogenesis. Bone 45(4):640-9. [PubMed: 19591967]  [MGI Ref ID J:154398]

Kevill KA; Bhandari V; Kettunen M; Leng L; Fan J; Mizue Y; Dzuira JD; Reyes-Mugica M; McDonald CL; Baugh JA; O'Connor CL; Aghai ZH; Donnelly SC; Bazzy-Asaad A; Bucala RJ. 2008. A role for macrophage migration inhibitory factor in the neonatal respiratory distress syndrome. J Immunol 180(1):601-8. [PubMed: 18097062]  [MGI Ref ID J:130907]

Koebernick H; Grode L; David JR; Rohde W; Rolph MS; Mittrucker HW; Kaufmann SH. 2002. Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc Natl Acad Sci U S A 99(21):13681-6. [PubMed: 12271144]  [MGI Ref ID J:126891]

Koga K; Kenessey A; Ojamaa K. 2013. Macrophage migration inhibitory factor antagonizes pressure overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 304(2):H282-93. [PubMed: 23144312]  [MGI Ref ID J:193147]

Longley R; Smith C; Fortin A; Berghout J; McMorran B; Burgio G; Foote S; Gros P. 2011. Host resistance to malaria: using mouse models to explore the host response. Mamm Genome 22(1-2):32-42. [PubMed: 21116636]  [MGI Ref ID J:168720]

Magalhaes ES; Mourao-Sa DS; Vieira-de-Abreu A; Figueiredo RT; Pires AL; Farias-Filho FA; Fonseca BP; Viola JP; Metz C; Martins MA; Castro-Faria-Neto HC; Bozza PT; Bozza MT. 2007. Macrophage migration inhibitory factor is essential for allergic asthma but not for Th2 differentiation. Eur J Immunol 37(4):1097-106. [PubMed: 17373669]  [MGI Ref ID J:120840]

Malu DT; Belanger B; Desautels F; Kelendji K; Dalko E; Sanchez-Dardon J; Leng L; Bucala R; Satoskar AR; Scorza T. 2011. Macrophage Migration Inhibitory Factor: A Downregulator of Early T Cell-Dependent IFN-{gamma} Responses in Plasmodium chabaudi adami (556 KA)-Infected Mice. J Immunol 186(11):6271-9. [PubMed: 21518974]  [MGI Ref ID J:173194]

Man AL; Lodi F; Bertelli E; Regoli M; Pin C; Mulholland F; Satoskar AR; Taussig MJ; Nicoletti C. 2008. Macrophage migration inhibitory factor plays a role in the regulation of microfold (M) cell-mediated transport in the gut. J Immunol 181(8):5673-80. [PubMed: 18832726]  [MGI Ref ID J:140754]

Martin J; Duncan FJ; Keiser T; Shin S; Kusewitt DF; Oberyszyn T; Satoskar AR; VanBuskirk AM. 2009. Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB) -induced nonmelanoma skin cancer (NMSC). FASEB J 23(3):720-30. [PubMed: 18952710]  [MGI Ref ID J:146020]

McDevitt MA; Xie J; Shanmugasundaram G; Griffith J; Liu A; McDonald C; Thuma P; Gordeuk VR; Metz CN; Mitchell R; Keefer J; David J; Leng L; Bucala R. 2006. A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. J Exp Med 203(5):1185-96. [PubMed: 16636133]  [MGI Ref ID J:124140]

Miller EJ; Li J; Leng L; McDonald C; Atsumi T; Bucala R; Young LH. 2008. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451(7178):578-82. [PubMed: 18235500]  [MGI Ref ID J:131830]

Paiva CN; Arras RH; Lessa LP; Gibaldi D; Alves L; Metz CN; Gazzinelli R; Pyrrho AS; Lannes-Vieira J; Bozza MT. 2007. Unraveling the lethal synergism between Trypanosoma cruzi infection and LPS: a role for increased macrophage reactivity. Eur J Immunol 37(5):1355-64. [PubMed: 17390393]  [MGI Ref ID J:123561]

Paiva CN; Arras RH; Magalhaes ES; Alves LS; Lessa LP; Silva MH; Ejzemberg R; Canetti C; Bozza MT. 2009. Migration inhibitory factor (MIF) released by macrophages upon recognition of immune complexes is critical to inflammation in Arthus reaction. J Leukoc Biol 85(5):855-61. [PubMed: 19188484]  [MGI Ref ID J:149693]

Pan JH; Sukhova GK; Yang JT; Wang B; Xie T; Fu H; Zhang Y; Satoskar AR; David JR; Metz CN; Bucala R; Fang K; Simon DI; Chapman HA; Libby P; Shi GP. 2004. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 109(25):3149-53. [PubMed: 15197138]  [MGI Ref ID J:102201]

Powell ND; Papenfuss TL; McClain MA; Gienapp IE; Shawler TM; Satoskar AR; Whitacre CC. 2005. Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J Immunol 175(9):5611-4. [PubMed: 16237048]  [MGI Ref ID J:119365]

Reyes JL; Terrazas LI; Espinoza B; Cruz-Robles D; Soto V; Rivera-Montoya I; Gomez-Garcia L; Snider H; Satoskar AR; Rodriguez-Sosa M. 2006. Macrophage migration inhibitory factor contributes to host defense against acute Trypanosoma cruzi infection. Infect Immun 74(6):3170-9. [PubMed: 16714544]  [MGI Ref ID J:109241]

Sanchez-Zamora Y; Terrazas LI; Vilches-Flores A; Leal E; Juarez I; Whitacre C; Kithcart A; Pruitt J; Sielecki T; Satoskar AR; Rodriguez-Sosa M. 2010. Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J 24(7):2583-90. [PubMed: 20203087]  [MGI Ref ID J:162358]

Shi X; Leng L; Wang T; Wang W; Du X; Li J; McDonald C; Chen Z; Murphy JW; Lolis E; Noble P; Knudson W; Bucala R. 2006. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25(4):595-606. [PubMed: 17045821]  [MGI Ref ID J:114878]

Stojanovic I; Cvjeticanin T; Lazaroski S; Stosic-Grujicic S; Miljkovic D. 2009. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology 126(1):74-83. [PubMed: 18624729]  [MGI Ref ID J:145486]

Sun H; Choo-Wing R; Sureshbabu A; Fan J; Leng L; Yu S; Jiang D; Noble P; Homer RJ; Bucala R; Bhandari V. 2013. A critical regulatory role for macrophage migration inhibitory factor in hyperoxia-induced injury in the developing murine lung. PLoS One 8(4):e60560. [PubMed: 23637753]  [MGI Ref ID J:200564]

Taylor JA 3rd; Kuchel GA; Hegde P; Voznesensky OS; Claffey K; Tsimikas J; Leng L; Bucala R; Pilbeam C. 2007. Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice. BMC Cancer 7:135. [PubMed: 17650334]  [MGI Ref ID J:126543]

Taylor JA; Zhu Q; Irwin B; Maghaydah Y; Tsimikas J; Pilbeam C; Leng L; Bucala R; Kuchel GA. 2006. Null mutation in macrophage migration inhibitory factor prevents muscle cell loss and fibrosis in partial bladder outlet obstruction. Am J Physiol Renal Physiol 291(6):F1343-53. [PubMed: 16835407]  [MGI Ref ID J:144686]

Turtzo LC; Li J; Persky R; Benashski S; Weston G; Bucala R; Venna VR; McCullough LD. 2013. Deletion of macrophage migration inhibitory factor worsens stroke outcome in female mice. Neurobiol Dis 54:421-31. [PubMed: 23376686]  [MGI Ref ID J:197860]

Vieira-de-Abreu A; Calheiros AS; Mesquita-Santos FP; Magalhaes ES; Mourao-Sa D; Castro-Faria-Neto HC; Bozza MT; Bandeira-Melo C; Bozza PT. 2011. Cross-talk between macrophage migration inhibitory factor and eotaxin in allergic eosinophil activation forms leukotriene C(4)-synthesizing lipid bodies. Am J Respir Cell Mol Biol 44(4):509-16. [PubMed: 20539011]  [MGI Ref ID J:183351]

Wang B; Huang X; Wolters PJ; Sun J; Kitamoto S; Yang M; Riese R; Leng L; Chapman HA; Finn PW; David JR; Bucala R; Shi GP. 2006. Cutting edge: Deficiency of macrophage migration inhibitory factor impairs murine airway allergic responses. J Immunol 177(9):5779-84. [PubMed: 17056501]  [MGI Ref ID J:140539]

Wang X; Chen T; Leng L; Fan J; Cao K; Duan Z; Zhang X; Shao C; Wu M; Tadmori I; Li T; Liang L; Sun D; Zheng S; Meinhardt A; Young W; Bucala R; Ren Y. 2012. MIF produced by bone marrow-derived macrophages contributes to teratoma progression after embryonic stem cell transplantation. Cancer Res 72(11):2867-78. [PubMed: 22461508]  [MGI Ref ID J:189342]

Wilson JM; Coletta PL; Cuthbert RJ; Scott N; MacLennan K; Hawcroft G; Leng L; Lubetsky JB; Jin KK; Lolis E; Medina F; Brieva JA; Poulsom R; Markham AF; Bucala R; Hull MA. 2005. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 129(5):1485-503. [PubMed: 16285950]  [MGI Ref ID J:103661]

de Jong YP; Abadia-Molina AC; Satoskar AR; Clarke K; Rietdijk ST; Faubion WA; Mizoguchi E; Metz CN; Alsahli M; ten Hove T; Keates AC; Lubetsky JB; Farrell RJ; Michetti P; van Deventer SJ; Lolis E; David JR; Bhan AK; Terhorst C. 2001. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2(11):1061-6. [PubMed: 11668338]  [MGI Ref ID J:126286]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryThis strain originated on a B6;129S4 background and has been backcrossed to BALB/cAnNTac mice for six generations before being made homozygous.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2525.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3283.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)